Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
239.62
+2.67 (1.13%)
Jul 22, 2026, 4:00 PM EDT - Market closed
Axsome Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 708.24 | 638.5 | 385.69 | 270.6 | 50.04 | - | |
Revenue Growth (YoY) | 63.88% | 65.55% | 42.53% | 440.80% | - | - |
Cost of Revenue | 52.41 | 47.48 | 33.3 | 26.07 | 5.2 | - |
Gross Profit | 655.82 | 591.02 | 352.39 | 244.54 | 44.84 | - |
Selling, General & Admin | 634.81 | 570.6 | 411.36 | 323.12 | 159.25 | 66.65 |
Depreciation & Amortization Expenses | 6.38 | 6.38 | 6.39 | 6.38 | 4.14 | - |
Research & Development | 191.17 | 183.28 | 187.08 | 97.94 | 57.95 | 58.06 |
Other Operating Expenses | -3.4 | -2.47 | 28.12 | 48.92 | 3.3 | - |
Total Operating Expenses | 828.96 | 757.78 | 632.95 | 476.36 | 224.64 | 124.71 |
Operating Income | -173.14 | -166.76 | -280.56 | -231.83 | -179.8 | -124.71 |
Interest Expense | -5.31 | -6.56 | -6.57 | -6.45 | -7.34 | -5.7 |
Other Non-Operating Income (Expense) | - | -10.39 | - | - | - | - |
Total Non-Operating Income (Expense) | -5.31 | -16.94 | -6.57 | -6.45 | -7.34 | -5.7 |
Pretax Income | -188.83 | -183.7 | -287.13 | -238.28 | -187.13 | -130.4 |
Provision for Income Taxes | -0.53 | -0.53 | 0.09 | 0.96 | - | - |
Net Income | -188.3 | -183.17 | -287.22 | -239.24 | -187.13 | -130.4 |
Net Income to Common | -188.3 | -183.17 | -287.22 | -239.24 | -187.13 | -130.4 |
Shares Outstanding (Basic) | 50 | 50 | 48 | 45 | 41 | 38 |
Shares Outstanding (Diluted) | 50 | 50 | 48 | 45 | 41 | 38 |
Shares Change (YoY) | 4.23% | 3.82% | 5.48% | 11.73% | 8.07% | 1.11% |
EPS (Basic) | -3.73 | -3.68 | -5.99 | -5.27 | -4.60 | -3.47 |
EPS (Diluted) | -3.73 | -3.68 | -5.99 | -5.27 | -4.60 | -3.47 |
Free Cash Flow | -70.99 | -93.89 | -128.68 | -145.66 | -117.21 | -108.53 |
Free Cash Flow Per Share | -1.41 | -1.89 | -2.69 | -3.21 | -2.88 | -2.89 |
Gross Margin | 92.60% | 92.56% | 91.37% | 90.37% | 89.61% | - |
Operating Margin | -24.45% | -26.12% | -72.74% | -85.67% | -359.33% | - |
Profit Margin | -26.59% | -28.69% | -74.47% | -88.41% | -373.99% | - |
FCF Margin | -10.02% | -14.70% | -33.36% | -53.83% | -234.25% | - |
EBITDA | -163.84 | -157.7 | -272.6 | -224.99 | -175.4 | -124.63 |
EBITDA Margin | -23.13% | -24.70% | -70.68% | -83.15% | -350.53% | - |
EBIT | -173.14 | -166.76 | -280.56 | -231.83 | -179.8 | -124.71 |
EBIT Margin | -24.45% | -26.12% | -72.74% | -85.67% | -359.33% | - |
Effective Tax Rate | 0.28% | 0.29% | -0.03% | -0.40% | 0.00% | 0.00% |